AdjuTec Pharma, Venus Remedies Partner to Evaluate APC-148 for AMR

AdjuTec Pharma, Venus Remedies Partner to Evaluate APC-148 for AMR

AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, announces that it has entered into a research collaboration agreement with Venus Remedies Limited (India).  The company will perform a pre-clinical evaluation of AdjuTec Pharma´s APC-148 platform technology.
 
AdjuTec Pharma has developed novel inhibitor technologies that selectively destroy antibiotic resistance mechanisms in multidrug-resistant bacteria, thereby restoring the effectiveness of commercially available antibiotics. APC-148 is the lead programme that is presently in phase 1 clinical trials. As a frontrunner in AMR, Venus will leverage its advanced R&D capabilities to assess APC-148’s potential in restoring the effectiveness of antibiotics against multidrug-resistant bacterial strains.
 
As part of this engagement, Venus will test APC-148 in combination with various antibiotics against its extensive library of clinical isolates collected through the GASAR study. The study forms part of Venus Remedies’ broader commitment to combating AMR and contributing to the UN’s ‘One Health’ objective.
 
AdjuTec Pharma and Venus Remedies Limited share a joint mission to address the global health threat against AMR. APC-148 has the potential to significantly restore the effectiveness of antibiotics against resistant bacterial strains that are increasingly burdening the Indian healthcare system.
 
Jethro Holter, CEO, AdjuTec Pharma AS, said: “This agreement perfectly aligns with our strategy to collaborate with leading and international pharmaceutical partners to address the most clinically challenging resistant pathogens through our groundbreaking technology.”
 
Saransh Chaudhary, president, Global critical care, Venus Remedies, and CEO, Venus Medicine Research Centre said: “This research engagement allows us to contribute our expertise in AMR toward advancing scientific understanding of novel solutions in this space. Our collaboration reflects a shared commitment to addressing the global AMR challenge through rigorous, innovation-driven research.

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!